Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 8, 2009 - Issue 1
Submit an article Journal homepage
584
Views
118
CrossRef citations to date
0
Altmetric
Reviews

How safe is the use of thiazolidinediones in clinical practice?

CV Rizos University of Ioannina, School of Medicine, Department of Internal Medicine, Ioannina 45110, Greece +30 26510 97509; +30 26510 97016; [email protected]
,
Moses Elisaf University of Ioannina, School of Medicine, Department of Internal Medicine, Ioannina 45110, Greece +30 26510 97509; +30 26510 97016; [email protected]
, MD FASA FRSH,
DP Mikhailidis University College London, University College Medical School, Royal Free Hospital campus, Department of Clinical Biochemistry, London, UK
&
EN Liberopoulos University of Ioannina, School of Medicine, Department of Internal Medicine, Ioannina 45110, Greece +30 26510 97509; +30 26510 97016; [email protected]
Pages 15-32 | Published online: 25 Nov 2008

Bibliography

  • Bertoni AG, Krop JS, Anderson GF, Brancati FL. Diabetes-related morbidity and mortality in a national sample of U.S. elders. Diabetes Care 2002;25:471-5
  • Schernthaner G. Cardiovascular mortality and morbidity in type-2 diabetes mellitus. Diabetes Res Clin Pract 1996;31(Suppl):S3-13
  • Virally M, Blickle JF, Girard J, et al. Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives. Diabetes Metab 2007;33:231-44
  • Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother 2008;9:1087-108
  • Decker M, Hofflich H, Elias AN. Thiazolidinediones and the preservation of beta-cell function, cellular proliferation and apoptosis. Diabetes Obes Metab 2008;10:617-25
  • Forman BM, Chen J, Evans RM. The peroxisome proliferator-activated receptors: ligands and activators. Ann NY Acad Sci 1996;804:266-75
  • Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2008;31:173-5
  • Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-8
  • Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003;108:2941-8
  • Schernthaner G, Matthews DR, Charbonnel B, et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004;89:6068-76
  • Aronoff S, Rosenblatt S, Braithwaite S, et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000;23:1605-11
  • Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89
  • Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572-81
  • Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008;299:1561-73
  • Gerstein HC, Yusuf S, Bosch J, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006;368:1096-105
  • Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
  • Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract 2007;76:279-89
  • Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24:1226-32
  • Marceille JR, Goins JA, Soni R, et al. Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin. Pharmacotherapy 2004;24:1317-22
  • Bell DS. Unilateral edema due to a thiazolidinedione. Diabetes Care 2003;26:2700
  • Abdallah MH, Khalil PB, Jamaleddine G, et al. Thiazolidinediones associated with recurrent pleural effusions post coronary artery bypass surgery. Int J Cardiol 2006;106:273-5
  • Young MM, Squassante L, Wemer J, et al. Troglitazone has no effect on red cell mass or other erythropoietic parameters. Eur J Clin Pharmacol 1999;55:101-4
  • Zanchi A, Chiolero A, Maillard M, et al. Effects of the peroxisomal proliferator-activated receptor-gamma agonist pioglitazone on renal and hormonal responses to salt in healthy men. J Clin Endocrinol Metab 2004;89:1140-5
  • Hosokawa M, Tsukada H, Fukuda K, et al. Troglitazone inhibits bicarbonate secretion in rat and human duodenum. J Pharmacol Exp Ther 1999;290:1080-4
  • Baba T, Shimada K, Neugebauer S, et al. The oral insulin sensitizer, thiazolidinedione, increases plasma vascular endothelial growth factor in type 2 diabetic patients. Diabetes Care 2001;24:953-4
  • Buchanan TA, Meehan WP, Jeng YY, et al. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 1995;96:354-60
  • Yang T, Michele DE, Park J, et al. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am J Physiol 1999;277:F966-73
  • Zhang H, Zhang A, Kohan DE, et al. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 2005;102:9406-11
  • Guan Y, Hao C, Cha DR, et al. Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005;11:861-6
  • Karalliedde J, Buckingham R, Starkie M, et al. Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol 2006;17:3482-90
  • Kleyman TR, Sheng S, Kosari F, Kieber-Emmons T. Mechanism of action of amiloride: a molecular prospective. Semin Nephrol 1999;19:524-32
  • Devereux RB, Roman MJ, Paranicas M, et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 2000;101:2271-6
  • Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001;24:1614-9
  • Bertoni AG, Hundley WG, Massing MW, et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004;27:699-703
  • Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 2007;30:2148-53
  • Important revisions to the full prescribing information (labeling) highlighting increased risks of congestive heart failure associated with rosiglitazone. Available from: http://www.fda.gov/cder/drug/InfoSheets/HCP/rosiglitazone200707HCP.htm. [Last accessed 6 July 2008]
  • Pioglitazone may cause or exacerbate heart failure, particularly in certain patient populations. Available from: http://www.fda.gov/cder/drug/InfoSheets/HCP/pioglitazoneHCP.htm. [Last accessed 6 July 2008]
  • Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95
  • Lipscombe LL, Gomes T, Levesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007;298:2634-43
  • Dagenais GR, Gerstein HC, Holman R, et al. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 2008;31:1007-14
  • Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8
  • Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005;111:583-90
  • Bauters C, Lamblin N, Mc Fadden EP, et al. Influence of diabetes mellitus on heart failure risk and outcome. Cardiovasc Diabetol 2003;2:1
  • Dargie HJ, Hildebrandt PR, Riegger GA, et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol 2007;49:1696-704
  • St John Sutton M, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002;25:2058-64
  • Avandia Product Information. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Avandia/H-268-PI-en.pdf. [Last accessed 12 July 2008]
  • Actos Product Information. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Actos/H-285-PI-en.pdf. [Last accessed 12 July 2008]
  • Kempen JH, O'Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004;122:552-63
  • Ferris FL 3rd, Patz A. Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol 1984;28(Suppl):452-61
  • Colucciello M. Vision loss due to macular edema induced by rosiglitazone treatment of diabetes mellitus. Arch Ophthalmol 2005;123:1273-5
  • Tatti P, Arrigoni F, Longobardi A, et al. Retrospective analysis of rosiglitazone and macular oedema in patients with type 2 diabetes mellitus. Clin Drug Investig 2008;28:327-32
  • Ryan EH Jr, Han DP, Ramsay RC, et al. Diabetic macular edema associated with glitazone use. Retina 2006;26:562-70
  • Sinaiko AR, Steinberger J, Moran A, et al. Relation of body mass index and insulin resistance to cardiovascular risk factors, inflammatory factors, and oxidative stress during adolescence. Circulation 2005;111:1985-91
  • Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006;7:211-228
  • Narayan KM, Boyle JP, Thompson TJ, et al. Effect of BMI on lifetime risk for diabetes in the US. Diabetes Care 2007;30:1562-6
  • Wilson PW, D'Agostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 2002;162:1867-72
  • Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 2003;115(Suppl 8A):S42-8
  • Shim WS, Do MY, Kim SK, et al. The long-term effects of rosiglitazone on serum lipid concentrations and body weight. Clin Endocrinol (Oxf) 2006;65:453-9
  • Reynolds LR, Konz EC, Frederich RC, Anderson JW. Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus. Diabetes Obes Metab 2002;4:270-5
  • Boden G, Homko C, Mozzoli M, et al. Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention. Diabetes 2007;56:248-55
  • Kendall DM, Rubin CJ, Mohideen P, et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study. Diabetes Care 2006;29:1016-23
  • Adams M, Montague CT, Prins JB, et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997;100:3149-53
  • De Koning L, Merchant AT, Pogue J, Anand SS. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J 2007;28:850-6
  • Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784-91
  • Shimizu H, Tsuchiya T, Sato N, et al. Troglitazone reduces plasma leptin concentration but increases hunger in NIDDM patients. Diabetes Care 1998;21:1470-4
  • Kusaka I, Nagasaka S, Horie H, Ishibashi S. Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability? Diabetes Obes Metab 2008 [Epub ahead of print]
  • Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001;409:194-8
  • Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001;86:5992
  • Rosenstock J, Shen SG, Gatlin MR, Foley JE. Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care 2002;25:1529-33
  • Berria R, Glass L, Mahankali A, et al. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Clin Pharmacol Ther 2007;82:275-81
  • Hollenberg NK. Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med 2003;115(Suppl 8A):S111-5
  • Gimble JM, Robinson CE, Wu X, et al. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 1996;50:1087-94
  • Berria R, Gastaldelli A, Lucidi S, et al. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. Clin Pharmacol Ther 2006;80:105-14
  • Liu X, Huang T, Sahud MA. Rosiglitazone-induced immune thrombocytopenia. Platelets 2006;17:143-8
  • Graham DJ, Green L, Senior JR, Nourjah P. Troglitazone-induced liver failure: a case study. Am J Med 2003;114:299-306
  • Graham DJ, Drinkard CR, Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterol 2003;98:175-9
  • Almdal TP, Sorensen TI. Incidence of parenchymal liver diseases in Denmark, 1981 to 1985: analysis of hospitalization registry data. The Danish Association for the Study of the Liver. Hepatology 1991;13:650-5
  • Beard K, Belic L, Aselton P, et al. Outpatient drug-induced parenchymal liver disease requiring hospitalization. J Clin Pharmacol 1986;26:633-7
  • Murphy EJ, Davern TJ, Shakil AO, et al. Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group. Dig Dis Sci 2000;45:549-53
  • Neuschwander-Tetri BA, Isley WL, Oki JC, et al. Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med 1998;129:38-41
  • Gitlin N, Julie NL, Spurr CL, et al. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 1998;129:36-8
  • Jagannath S, Rai R. Rapid-onset subfulminant liver failure associated with troglitazone. Ann Intern Med 2000;132:677
  • Kassahun K, Pearson PG, Tang W, et al. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem Res Toxicol 2001;14:62-70
  • Toyoda Y, Tsuchida A, Iwami E, Miwa I. Toxic effect of troglitazone on cultured rat hepatocytes. Life Sci 2001;68:1867-76
  • Yamamoto Y, Nakajima M, Yamazaki H, Yokoi T. Cytotoxicity and apoptosis produced by troglitazone in human hepatoma cells. Life Sci 2001;70:471-82
  • Smith MT. Mechanisms of troglitazone hepatotoxicity. Chem Res Toxicol 2003;16:679-87
  • Chojkier M. Troglitazone and liver injury: in search of answers. Hepatology 2005;41:237-46
  • Bissell DM, Gores GJ, Laskin DL, Hoofnagle JH. Drug-induced liver injury: mechanisms and test systems. Hepatology 2001;33:1009-13
  • Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf 2001;24:483-90
  • Kohlroser J, Mathai J, Reichheld J, et al. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 2000;95:272-6
  • Diakou MC, Liberopoulos EN, Mikhailidis DP, et al. Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence. Scand J Gastroenterol 2007;42:139-47
  • Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-17
  • Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-96
  • El-Naggar MH, Helmy A, Moawad M, et al. Late-onset rosiglitazone-associated acute liver failure in a patient with Hodgkin's lymphoma. Ann Pharmacother 2008;42:713-8
  • Farley-Hills E, Sivasankar R, Martin M. Fatal liver failure associated with pioglitazone. BMJ 2004;329:429
  • Dhawan M, Agrawal R, Ravi J, et al. Rosiglitazone-induced granulomatous hepatitis. J Clin Gastroenterol 2002;34:582-4
  • May LD, Lefkowitch JH, Kram MT, Rubin DE. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002;136:449-52
  • Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45
  • Danan G, Benichou C. Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-30
  • Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int 2007;18:427-44
  • Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006;91:3349-54
  • Sornay-Rendu E, Munoz F, Duboeuf F, Delmas PD. Rate of forearm bone loss is associated with an increased risk of fracture independently of bone mass in postmenopausal women: the OFELY study. J Bone Miner Res 2005;20:1929-35
  • Kahn SE, Zinman B, Lachin JM, et al. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008;31:845-51
  • Landis DM. Fracture risk in postmenopausal women. Nurse Pract 2005;30:53-8
  • Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2007;92:1305-10
  • Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 2007;30:1574-6
  • Meier C, Kraenzlin ME, Bodmer M, et al. Use of thiazolidinediones and fracture risk. Arch Intern Med 2008;168:820-5
  • Okazaki R, Miura M, Toriumi M, et al. Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus. Endocr J 1999;46:795-801
  • Murphy CE, Rodgers PT. Effects of thiazolidinediones on bone loss and fracture. Ann Pharmacother 2007;41:2014-8
  • Rzonca SO, Suva LJ, Gaddy D, et al. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004;145:401-6
  • Lecka-Czernik B, Gubrij I, Moerman EJ, et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem 1999;74:357-71
  • Pasco JA, Henry MJ, Nicholson GC. Weight gain may contribute to increased fracture risk in women treated with rosiglitazone. Diabet Med 2007;24:1173-4
  • Quinn CE, Hamilton PK, Lockhart CJ, McVeigh GE. Thiazolidinediones: effects on insulin resistance and the cardiovascular system. Br J Pharmacol 2008;153:636-45
  • Cornish J, Callon KE, Reid IR. Insulin increases histomorphometric indices of bone formation In vivo. Calcif Tissue Int 1996;59:492-5
  • Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-8
  • Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 2003;52:453-62
  • Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004;27:1496-504
  • Siegel RD, Cupples A, Schaefer EJ, Wilson PW. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism 1996;45:1267-72
  • Gazi IF, Tsimihodimos V, Tselepis AD, et al. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 2007;7:53-72
  • Van Wijk JP, De Koning EJ, Martens EP, Rabelink TJ. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003;23:1744-9
  • Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54
  • Gutschi LM, Malcolm JC, Favreau CM, Ooi TC. Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy. Ann Pharmacother 2006;40:1672-6
  • Sarker A, Semple RK, Dinneen SF, et al. Severe hypo-alpha-lipoproteinemia during treatment with rosiglitazone. Diabetes Care 2004;27:2577-80
  • Shetty C, Balasubramani M, Capps N, et al. Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment. Diabet Med 2007;24:94-7
  • Qin S, Liu T, Kamanna VS, Kashyap ML. Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha. Arterioscler Thromb Vasc Biol 2007;27:2428-34
  • Sakamoto J, Kimura H, Moriyama S, et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000;278:704-11
  • Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 2002;18:269-76
  • Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease – a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 2007;154:943-53
  • Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
  • GlaxoSmithKline. GlaxoSmithKline clinical trial register: study No. ZM2005/00181/01, Avandia Cardiovascular Event Modeling Project, and study No. HM2006/00497/00/WEUSRTP866, Coronary Heart Disease Outcomes in Patients Receiving Antidiabetic Agents.; Available from: http://ctr.gsk.co.uk/Summary/Rosiglitazone/III_CVmodeling.pdf. [Last accessed 13 July 2008]
  • Division of Metabolism and Endocrine Products and Office of Surveillance and Epidemiology, US Food and Drug Administration. FDA Briefing Document: joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee. July 30, 2007. Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4308b1-02-fda-backgrounder.pdf. [Last accessed 11 January 2008]
  • Bhatt DL, Chew DP, Grines C, et al. Peroxisome proliferator-activated receptor gamma agonists for the prevention of adverse events following percutaneous coronary revascularization – results of the PPAR study. Am Heart J 2007;154:137-43
  • Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med 2007;357:28-38
  • Bertrand O, Poirier P, Despres JP, Investigators V. Results of a multicenter randomized double-blind placebo-controlled study to assess the benefit and safety of rosiglitazone in preventing atherosclerosis progression after coronary artery bypass surgery in type 2 diabetes. In: American College of Cardiology 2008 Scientific Sessions; 2008; Chicago, IL
  • Erdmann E, Dormandy JA, Charbonnel B, et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007;49:1772-80
  • Gerrits CM, Bhattacharya M, Manthena S, et al. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007;16:1065-71
  • FDA Adds Boxed Warning for Heart-related Risks to Anti-Diabetes Drug Avandia. Available from: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01743.html. [Last accessed 31 May 2008]
  • EMEA recommends new warnings and contraindications for rosiglitazone. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/avaglim/4223208en.pdf. [Last accessed 31 May 2008]
  • European Medicines Agency confirms positive benefit-risk balance for rosiglitazone and pioglitazone. Available from: http://www.emea.europa.eu/pdfs/human/press/pr/48427707en.pdf. [Last accessed 31 May 2008]
  • Derosa G, D'Angelo A, Ragonesi PD, et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006;31:375-83
  • Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 1998;82:U57-66
  • Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000;106:453-8
  • Kakafika AI, Liberopoulos EN, Karagiannis A, et al. Dyslipidaemia, hypercoagulability and the metabolic syndrome. Curr Vasc Pharmacol 2006;4:175-83
  • Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007;38:865-73
  • Lee J, Reding M. Effects of thiazolidinediones on stroke recovery: a case-matched controlled study. Neurochem Res 2007;32:635-8
  • Allahtavakoli M, Shabanzadeh AP, Sadr SS, et al. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma ligand, reduces infarction volume and neurological deficits in an embolic model of stroke. Clin Exp Pharmacol Physiol 2006;33:1052-8
  • Luo Y, Yin W, Signore AP, et al. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem 2006;97:435-48
  • Govindarajan R, Ratnasinghe L, Simmons DL, et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007;25:1476-81
  • Mac Lean CD, Littenberg B, Gagnon M, et al. The Vermont Diabetes Information System (VDIS): study design and subject recruitment for a cluster randomized trial of a decision support system in a regional sample of primary care practices. Clin Trials 2004;1:532-44
  • Ramos-Nino ME, Mac Lean CD, Littenberg B. Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC Med 2007;5:17
  • Monami M, Lamanna C, Marchionni N, Mannucci E. Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care 2008;31:1455-60
  • Dorkhan M, Dencker M, Frid A. Treatment with pioglitazone induced significant, reversible mitral regurgitation. Cardiovasc Diabetol 2008;7:12
  • Kaplan B, Friedman G, Jacobs M, et al. Potential interaction of troglitazone and cyclosporine. Transplantation 1998;65:1399-400
  • Hoffmann TK, Parker DL, Buch HA, Balusu P. Suspected suppression of the INR by thiazolidinediones: interaction between warfarin and TZDs. Ann Pharmacother 2006;40:994-6
  • Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002;18(Suppl 2):S23-9
  • Deng LJ, Wang F, Li HD. Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur J Clin Pharmacol 2005;61:831-6
  • Niemi M, Backman JT, Granfors M, et al. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 2003;46:1319-23
  • Jaakkola T, Backman JT, Neuvonen M, et al. Effect of rifampicin on the pharmacokinetics of pioglitazone. Br J Clin Pharmacol 2006;61:70-8
  • Ledl M, Hohenecker J, Francesconi C, et al. Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone. Diabetologia 2005;48:1996-8
  • Koro CE, Sowell MO, Stender M, Qizilbash N. The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis. Clin Ther 2008;30:535-42
  • Shadid S, Jensen MD. Angioneurotic edema as a side effect of pioglitazone. Diabetes Care 2002;25:405
  • Ota H, Goto T, Yoshioka T, Ohyama N. Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome. Fertil Steril 2008 [Epub ahead of print]
  • GlaxoSmithKline. Prescribing information for Avandia (rosiglitazone maleate). Available from: http://us.gsk.com/products/assets/us_avandia.pdf. [Last accessed 30 April 2008]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.